Skip to content

Study · Measured the body's own peptide · 2004

3 results

GABA selectively controls the secretory activity of oxytocin neurons in the rat supraoptic nucleus.

Engelmann M, Bull PM, Brown CH, Landgraf R, Horn TF, Singewald N, Ludwig M, Wotjak CT

The European journal of neuroscience1 Feb 2004Cited by 22 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Natural levels measured3

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01AnimalEndogenous levelAnimal study (in vivo)Mechanism

    In rats, bicuculline given into the supraoptic nucleus significantly increased oxytocin release within the nucleus under basal conditions and during stress.

    In plain wordsIn rats, blocking GABA receptors in one brain area raised the release of the body's own oxytocin inside that area.

    Peptide
    Oxytocin
    Outcome
    IncreaseOxytocin release within the SON after GABAA antagonist bicuculline
    Study

    ratn: not reported in source

    Male Wistar rats, microdialysis and electrophysiology
    Comparator
    Basal values
    Outcome group
    Brain and neuronal activity · Nervous system and cognition

    Source sentences

    Summary
    This approach caused a significant increase in the release of OXT both within the SON and into the blood under basal conditions and during stress (up to 300 and 200%, respectively; P < 0.05 vs. basal values)
    2 context sentences
    Summary · context
    To further investigate the regulatory mechanisms underlying this dissociated release, we exposed male Wistar rats to a 30-min social defeat and monitored release of the inhibitory amino acids gamma amino butyric acid (GABA) and taurine within the hypothalamic supraoptic nucleus (SON) using microdialysis.
    Summary · context
    To reveal the physiological significance of centrally released GABA, the specific GABAA-receptor antagonist bicuculline (0.02 mm) was administered into the SON via retrodialysis.

    This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.

  2. 02AnimalEndogenous levelAnimal study (in vivo)Mechanism

    In rats, bicuculline given into the supraoptic nucleus significantly increased oxytocin release into the blood under basal conditions and during stress.

    In plain wordsIn rats, blocking GABA receptors in one brain area raised the body's own oxytocin in the blood.

    Peptide
    Oxytocin
    Outcome
    IncreasePlasma oxytocin release after GABAA antagonist bicuculline in the SON
    Study

    ratn: not reported in source

    Male Wistar rats, microdialysis and electrophysiology
    Comparator
    Basal values
    Outcome group
    Brain and neuronal activity · Nervous system and cognition

    Source sentences

    Summary
    This approach caused a significant increase in the release of OXT both within the SON and into the blood under basal conditions and during stress (up to 300 and 200%, respectively; P < 0.05 vs. basal values)
    2 context sentences
    Summary · context
    To further investigate the regulatory mechanisms underlying this dissociated release, we exposed male Wistar rats to a 30-min social defeat and monitored release of the inhibitory amino acids gamma amino butyric acid (GABA) and taurine within the hypothalamic supraoptic nucleus (SON) using microdialysis.
    Summary · context
    To reveal the physiological significance of centrally released GABA, the specific GABAA-receptor antagonist bicuculline (0.02 mm) was administered into the SON via retrodialysis.

    This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.

  3. 03AnimalEndogenous levelAnimal study (in vivo)Mechanism

    In rats, electrophysiological recordings confirmed a selective action of bicuculline on the firing activity of oxytocin neurons in the supraoptic nucleus; the direction is not stated.

    In plain wordsIn rats, blocking GABA receptors acted on the firing of the brain's own oxytocin-making neurones; the abstract does not give the direction.

    Peptide
    Oxytocin
    Outcome
    Direction not reportedFiring activity of OXT neurons after bicuculline
    Study

    ratn: not reported in source

    Male Wistar rats, microdialysis and electrophysiology
    Outcome group
    Brain and neuronal activity · Nervous system and cognition

    Source sentences

    Summary
    Electrophysiological studies confirmed the selective action of bicuculline on the firing activity of OXT neurons in the SON.
    2 context sentences
    Summary · context
    To further investigate the regulatory mechanisms underlying this dissociated release, we exposed male Wistar rats to a 30-min social defeat and monitored release of the inhibitory amino acids gamma amino butyric acid (GABA) and taurine within the hypothalamic supraoptic nucleus (SON) using microdialysis.
    Summary · context
    To reveal the physiological significance of centrally released GABA, the specific GABAA-receptor antagonist bicuculline (0.02 mm) was administered into the SON via retrodialysis.

    This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 20:03 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:51 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.